Thermo Fisher Scientific, Inc. (TMO)

$568

-4.05

(-0.71%)

Market is closed - opens 7 PM, 18 Jun 2024
star icon

Thermo Fisher Scientific Inc. is a global biotechnology company that provides a range of scientific research products and services.

Insights on Thermo Fisher Scientific, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 10.88B → 10.34B (in $), with an average decrease of 5.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 1.71B → 1.32B (in $), with an average decrease of 11.7% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 8.8% return, outperforming this stock by 3.1%

Performance

  • $564.90
    $569.11
    $568.00
    downward going graph

    0.55%

    Downside

    Day's Volatility :0.74%

    Upside

    0.2%

    downward going graph
  • $414.76
    $603.01
    $568.00
    downward going graph

    26.98%

    Downside

    52 Weeks Volatility :31.22%

    Upside

    5.81%

    downward going graph

Returns

PeriodThermo Fisher Scientific, Inc.Sector (Health Care)S&P500
3 Months
-2.08%
0.6%
6.3%
6 Months
9.52%
8.9%
15.5%
1 Year
7.7%
10.2%
24.1%
3 Years
17.73%
17.8%
31.4%

Highlights

Market Capitalization
218.4B
Book Value
$119.24
Dividend Share
1.44
Dividend Yield
0.27%
Earnings Per Share (EPS)
15.62
PE Ratio
36.62
PEG Ratio
2.81
Wall Street Target Price
626.25
Profit Margin
14.2%
Operating Margin TTM
16.68%
Return On Assets TTM
4.82%
Return On Equity TTM
13.62%
Revenue TTM
42.5B
Revenue Per Share TTM
110.37
Quarterly Revenue Growth YOY
-3.4000000000000004%
Gross Profit TTM
19.0B
EBITDA
10.8B
Diluted Eps TTM
15.62
Quarterly Earnings Growth YOY
0.04
EPS Estimate Current Year
21.72
EPS Estimate Next Year
24.33
EPS Estimate Current Quarter
4.71
EPS Estimate Next Quarter
5.12

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 32 Wall street analysts offering stock ratings for Thermo Fisher Scientific, Inc.(by analysts ranked 0 to 5 stars)
Based on 32 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
22
23
23
Hold
10
9
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 10.26%

Current $568.00
Target $626.25

Company Financials

FY18Y/Y Change
Revenue
24.4B
↑ 16.45%
Net Income
2.9B
↑ 32.04%
Net Profit Margin
12.06%
↑ 1.42%
FY19Y/Y Change
Revenue
25.5B
↑ 4.86%
Net Income
3.7B
↑ 25.8%
Net Profit Margin
14.47%
↑ 2.41%
FY20Y/Y Change
Revenue
32.2B
↑ 26.14%
Net Income
6.4B
↑ 72.48%
Net Profit Margin
19.79%
↑ 5.32%
FY21Y/Y Change
Revenue
39.2B
↑ 21.71%
Net Income
7.7B
↑ 21.18%
Net Profit Margin
19.7%
↓ 0.09%
FY22Y/Y Change
Revenue
44.9B
↑ 14.55%
Net Income
7.0B
↓ 10.03%
Net Profit Margin
15.47%
↓ 4.23%
FY23Y/Y Change
Revenue
42.9B
↓ 4.58%
Net Income
6.0B
↓ 13.74%
Net Profit Margin
13.99%
↓ 1.48%
Q4 FY22Q/Q Change
Revenue
11.5B
↑ 7.24%
Net Income
1.6B
↑ 5.42%
Net Profit Margin
13.76%
↓ 0.24%
Q1 FY23Q/Q Change
Revenue
10.7B
↓ 6.46%
Net Income
1.3B
↓ 18.21%
Net Profit Margin
12.04%
↓ 1.72%
Q2 FY23Q/Q Change
Revenue
10.7B
↓ 0.21%
Net Income
1.4B
↑ 5.59%
Net Profit Margin
12.74%
↑ 0.7%
Q3 FY23Q/Q Change
Revenue
10.6B
↓ 1.06%
Net Income
1.7B
↑ 26.01%
Net Profit Margin
16.22%
↑ 3.48%
Q4 FY23Q/Q Change
Revenue
10.9B
↑ 2.95%
Net Income
1.6B
↓ 4.96%
Net Profit Margin
14.97%
↓ 1.25%
Q1 FY24Q/Q Change
Revenue
10.3B
↓ 4.97%
Net Income
1.3B
↓ 18.53%
Net Profit Margin
12.84%
↓ 2.13%
FY18Y/Y Change
Total Assets
56.2B
↓ 0.77%
Total Liabilities
28.6B
↓ 8.35%
FY19Y/Y Change
Total Assets
58.4B
↑ 3.82%
Total Liabilities
28.7B
↑ 0.21%
FY20Y/Y Change
Total Assets
69.1B
↑ 18.28%
Total Liabilities
34.5B
↑ 20.31%
FY21Y/Y Change
Total Assets
95.1B
↑ 37.76%
Total Liabilities
54.1B
↑ 56.79%
FY22Y/Y Change
Total Assets
97.2B
↑ 2.14%
Total Liabilities
53.0B
↓ 2.11%
FY23Y/Y Change
Total Assets
98.7B
↑ 1.62%
Total Liabilities
51.9B
↓ 2.12%
Q4 FY22Q/Q Change
Total Assets
97.2B
↑ 7.31%
Total Liabilities
53.0B
↑ 13.24%
Q1 FY23Q/Q Change
Total Assets
94.7B
↓ 2.57%
Total Liabilities
52.2B
↓ 1.47%
Q2 FY23Q/Q Change
Total Assets
94.1B
↓ 0.58%
Total Liabilities
50.2B
↓ 3.9%
Q3 FY23Q/Q Change
Total Assets
97.1B
↑ 3.14%
Total Liabilities
51.6B
↑ 2.8%
Q4 FY23Q/Q Change
Total Assets
98.7B
↑ 1.72%
Total Liabilities
51.9B
↑ 0.56%
Q1 FY24Q/Q Change
Total Assets
97.1B
↓ 1.65%
Total Liabilities
51.5B
↓ 0.79%
FY18Y/Y Change
Operating Cash Flow
4.5B
↑ 13.43%
Investing Cash Flow
-1.3B
↓ 83.79%
Financing Cash Flow
-2.2B
↓ 158.04%
FY19Y/Y Change
Operating Cash Flow
5.0B
↑ 9.47%
Investing Cash Flow
-1.5B
↑ 18.68%
Financing Cash Flow
-3.1B
↑ 39.38%
FY20Y/Y Change
Operating Cash Flow
8.3B
↑ 66.68%
Investing Cash Flow
-1.5B
↑ 1.55%
Financing Cash Flow
959.0M
↓ 130.76%
FY21Y/Y Change
Operating Cash Flow
9.5B
↑ 15.13%
Investing Cash Flow
-21.9B
↑ 1352.45%
Financing Cash Flow
6.6B
↑ 586.24%
FY22Y/Y Change
Operating Cash Flow
9.2B
↓ 4.08%
Investing Cash Flow
-2.2B
↓ 90.16%
Financing Cash Flow
-2.8B
↓ 142.7%
Q4 FY22Q/Q Change
Operating Cash Flow
3.5B
↑ 80.02%
Investing Cash Flow
-2.2B
↑ 296.15%
Financing Cash Flow
2.4B
↓ 1683.44%
Q1 FY23Q/Q Change
Operating Cash Flow
729.0M
↓ 79.09%
Investing Cash Flow
-3.1B
↑ 45.53%
Financing Cash Flow
-2.6B
↓ 208.45%
Q2 FY23Q/Q Change
Operating Cash Flow
1.5B
↑ 111.25%
Investing Cash Flow
-3.6B
↑ 14.1%
Financing Cash Flow
-1.5B
↓ 43.85%
Q3 FY23Q/Q Change
Operating Cash Flow
2.4B
↑ 56.75%
Investing Cash Flow
-4.8B
↑ 32.94%
Financing Cash Flow
1.9B
↓ 227.4%

Technicals Summary

Sell

Neutral

Buy

Thermo Fisher Scientific, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.38%
9.52%
7.7%
17.73%
96.4%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.86%
-6.6%
4.59%
-16.09%
86.98%
Agilent Technologies Inc.
Agilent Technologies Inc.
-14.75%
-4.14%
11.57%
-9.09%
83.33%
Danaher Corp.
Danaher Corp.
-4.86%
12.22%
7.41%
-1.11%
80.22%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-7.29%
-5.6%
-0.75%
-10.99%
46.45%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.62
36.62
2.81
21.72
0.14
0.05
0.0
119.24
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.79
48.79
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
30.94
30.94
2.7
5.23
0.21
0.08
0.01
21.31
Danaher Corp.
Danaher Corp.
46.76
46.76
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.14
29.14
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$218.4B
96.4%
36.62
14.2%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.6B
86.98%
48.79
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.1B
83.33%
30.94
18.84%
Danaher Corp.
Danaher Corp.
Buy
$188.8B
80.22%
46.76
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$38.9B
46.45%
29.14
9.01%

Institutional Holdings

  • Vanguard Group Inc

    8.67%
  • BlackRock Inc

    7.59%
  • State Street Corporation

    4.34%
  • Capital World Investors

    3.54%
  • Morgan Stanley - Brokerage Accounts

    3.08%
  • T. Rowe Price Associates, Inc.

    2.63%

Corporate Announcements

  • Thermo Fisher Scientific, Inc. Dividends March,2024

    In the quarter ending March,2024. Thermo Fisher Scientific, Inc. has declared dividend of $0.39

    Read More

Company Information

The Company was the product of a merger between parent companies Thermo Electron & Fisher Scientific in 2006. Among Thermo Electron's product offerings were analytical and laboratory instruments. Its revenues in 2004 totalled $2 billion. Fisher Scientific was founded in 1902. It provides laboratory equipment and associated services. The resultant Company is in the healthcare industry, specialising in diagnostic and research. The Company's segments are life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services. Over the years, 65 companies were acquired by Thermo Fisher Scientific, including 13 in just the past five years. Private equity firms funded approximately 22 acquisitions. Additionally, eight assets were divested. A $17.4 billion acquisition in 2021 was Thermo Fisher Scientific's largest acquisition to date. The most recent acquisitions are Mesa Biotech and the European Viral Vector business. Currently, the Company has more than 4,00,000 customers around the world. It has employed over 75,000 people. North America accounts for more than half of the Company's sales. The Company's core markets are pharmaceuticals, biotechs, diagnostics, health care, academics, and government. It stands in line with companies such as Abbott Laboratories, Becton Dickinson & Agilent Technologies. Currently Thermo Fisher Scientific, Inc. has a market cap of $218.36 Billion. It has a P.E ratio of 36.19. The shares of Thermo Fisher Scientific, Inc. are trading at $568.0. .

Organization
Thermo Fisher Scientific, Inc.
Employees
122000
CEO
Mr. Marc N. Casper
Industry
Health Technology

FAQs